NCT02752763

Brief Summary

Dry eye is a significant adverse effect of isotretinoin causing patients to use ophthalmic medications. For this reason, many patients using isotretinoin are referred to ophthalmology clinic because of discomfort symptoms. In the literature, there are studies suggesting superiority of Autologous serum drops regarding effects on ocular surface when compared to artificial tear. In addition, Autologous serum was also used in several corneal pathologies with successful outcomes. No data regarding use in the ocular adverse effects of isotretinoin was found in the literature; however, investigators think that it may be an effective alternative in the treatment of dry eye developed during isotretinoin use due to positive effects on ocular surface, epithelial regeneration and anti-inflammatory effect. Autologous serum can be a choice of ophthalmologists in routine practice by increasing number of comprehensive studies investigating effectiveness, safety and long-terms effects of Autologous serum therapy.In this study, it was aimed to investigate dry eye development in the patients receiving systemic retinoic acid therapy and to compare effectiveness of Autologous serum and Preservative free artificial tear in the patients with dry eye disease.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Oct 2015

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2015

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2016

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

March 31, 2016

Completed
27 days until next milestone

First Posted

Study publicly available on registry

April 27, 2016

Completed
Last Updated

April 27, 2016

Status Verified

April 1, 2016

Enrollment Period

5 months

First QC Date

March 31, 2016

Last Update Submit

April 26, 2016

Conditions

Keywords

Dry eyeisotretinoin, ASAutologous serum

Outcome Measures

Primary Outcomes (3)

  • Change in Schirmer Test I in Patients with Dry Eye due to isotretinoin use after autologous serum or preservative free artificial tears treatment

    Schirmer Test I is used for Dry Eye evaluation before and after autologous serum or preservative free artificial tears treatment. Schirmer test is used to measure tear secretion. Schirmer strips are used for this test. Wetting of the paper is recorded in millimeter

    up to 3 Months monthly measurements were done

  • Change in Break up Time in Patients with Dry Eye due to isotretinoin use after autologous serum or preservative free artificial tears treatment

    fluorescein sodium eye drops was used for measurement of Break up Time. Value of Break up Time for per eye is recorded as seconds

    up to 3 Months monthly measurements were done

  • Change in Ocular surface Disease Index in Patients with Dry Eye due to isotretinoin use after autologous serum or preservative free artificial tears treatment

    OSDI score is a reliable and feasible test which is commonly used for dry eye patients to grade either dry eye symptom severity and its effect on vision-related function. In this index, people are asked to indicate whether they experienced any of the symptoms or problems due to drye eye, if so, how often. Every question asked to patients is scored from one to four according to the frequency of symptoms. The scores were collected from all the questions.

    up to 3 Months monthly measurements were done

Study Arms (2)

preservative free artificial tear drop

EXPERIMENTAL

preservative free artificial tears drop is a drop group declaring different kind of active agent like hydroxypropyl methylcellulose, carboxymethyl cellulose etc commonly used in dry eye treatment. Preservative free artificial tear( carboxymethyl cellulose, hydroxypropyl methylcellulose) was used as four times one drop daily. In our study, we prescribed to patients preservative free artificial tears drop(hydroxypropyl methylcellulose or carboxymethyl cellulose) four times one drop daily.

Drug: Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)

%40 Autologous serum(AS)

EXPERIMENTAL

peripheral venous blood (14-20 ml) that drawn from antecubital vein of patients to prepare Autologous Serum. Blood sample was left at room temperature over 2 hours for clotting. Serum was obtained after centrifugation at 4000 revolutions per minute (rpm) for 10 minutes at 4 °C using a Nuve NF1200R. Next, in a laminar flow cabinet under sterile conditions, approximately 10 mL of supernatant was collected and diluted to 40 % with isotonic saline solution. It is recommended for dry eye diseases, too. %40 diluted Autologous Serum used as four times one drop daily.

Drug: %40 diluted Autologous serum

Interventions

Serum that obtained after centrifugation of blood sample

%40 Autologous serum(AS)

Preservative free artificial tears is a group naming for drops commonly used for drye disease

Also known as: Tears naturale free(hydroxypropyl methylcellulose), Refresh single dose(polyvinyl Alcohol + Povidone)
preservative free artificial tear drop

Eligibility Criteria

Age18 Years - 35 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • isotretinoin use for any reason

You may not qualify if:

  • corneal pathologies such as dry eye illness before isotretinoin treatment
  • previous cornea surgery, injury or keratitis
  • active ocular infection
  • meibomian gland dysfunction
  • excessive allergic reaction that may be associated with dry eye
  • glaucoma therapy use
  • severe anemia
  • previously use of PFAT or AS for any reason
  • (Hb\<10 g/dL) and elevated hepatic function tests requiring withdrawal of therapy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Niğde State Hospital

Niğde, Niğde Province, 51100, Turkey (Türkiye)

Location

Related Publications (5)

  • Oner AF, Ferahbas A, Karakucuk S, Utas S, Karaman B, Kutlugun C et al. Ocular side effects associated with systemic isotretinoin. Cutan Ocul Toxicol. 2005;23:189-195.

    BACKGROUND
  • Egger SF, Huber-Spitzy V, Bohler K, Scholda C. [Isotretinoin administration in treatment of acne vulgaris. A prospective study of the kind and extent of ocular complications]. Ophthalmologe. 1995 Feb;92(1):17-20. German.

    PMID: 7719068BACKGROUND
  • Tananuvat N, Daniell M, Sullivan LJ, Yi Q, McKelvie P, McCarty DJ, Taylor HR. Controlled study of the use of autologous serum in dry eye patients. Cornea. 2001 Nov;20(8):802-6. doi: 10.1097/00003226-200111000-00005.

    PMID: 11685055BACKGROUND
  • Kojima T, Ishida R, Dogru M, Goto E, Matsumoto Y, Kaido M, Tsubota K. The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study. Am J Ophthalmol. 2005 Feb;139(2):242-6. doi: 10.1016/j.ajo.2004.08.040.

    PMID: 15733983BACKGROUND
  • Urzua CA, Vasquez DH, Huidobro A, Hernandez H, Alfaro J. Randomized double-blind clinical trial of autologous serum versus artificial tears in dry eye syndrome. Curr Eye Res. 2012 Aug;37(8):684-8. doi: 10.3109/02713683.2012.674609. Epub 2012 Jun 6.

    PMID: 22670856BACKGROUND

MeSH Terms

Conditions

Dry Eye Syndromes

Interventions

Ophthalmic SolutionsPolyvinyl AlcoholPovidone

Condition Hierarchy (Ancestors)

Lacrimal Apparatus DiseasesEye Diseases

Intervention Hierarchy (Ancestors)

Pharmaceutical SolutionsSolutionsPharmaceutical PreparationsTherapeutic UsesPharmacologic ActionsChemical Actions and UsesSpecialty Uses of ChemicalsAlcoholsOrganic ChemicalsPolyvinylsVinyl CompoundsAlkenesHydrocarbons, AcyclicHydrocarbonsPlasticsPolymersMacromolecular SubstancesBiomedical and Dental MaterialsManufactured MaterialsTechnology, Industry, and AgriculturePyrrolidinonesPyrrolidinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Uğur Yılmaz, M.D.

    Niğde State Hospital

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Opthalmologist M.D.

Study Record Dates

First Submitted

March 31, 2016

First Posted

April 27, 2016

Study Start

October 1, 2015

Primary Completion

March 1, 2016

Study Completion

March 1, 2016

Last Updated

April 27, 2016

Record last verified: 2016-04

Locations